SCIENION Appoints Frauke Hein as CEO

Dr. Frauke Hein is an executive, investor and entrepreneur in the life science industry with a track record of achievements in management, business, research and development, and is highly regarded for her leadership skills and business management experience.

She joins SCIENION from her former position as Chief Business Officer at Adrenomed AG, a clinical stage biotech company she cofounded in 2009, pioneering the development of a precision medicine guided first-in-class drug. Previously Frauke Hein gained expertise at the diagnostic company BRAHMS AG and global life science corporation Thermo Fisher Scientific as Director R&D at both companies. Before that she served as Director Life Sciences at Brandenburg Economic Development Board, advising financing and strategic planning for innovative biotech and medtech start-ups including technology and market assessment for Venture Capital. Frauke Hein studied biology at Westfälische Wilhelms University of Münster and holds a Diploma in Biology and a PhD in Biology with focus on biochemistry, biotechnology and molecular biology.  

At SCIENION, Hein will assume leadership over the business organization and core corporate functions. She will use her deep experience working with global companies to drive SCIENION’s growth, expand the company’s suite of products, and serve customers who are scaling businesses in today’s life science markets, all in close collaboration with Eickhoff.

“I have known Frauke professionally for over 20 years and have great admiration and respect for her accomplishments and her values. We share a vision of how the life sciences and diagnostics world is transforming global health, how technology providers have a bigger role to play, and how today’s great companies must be built around customer and employee centricity. I am excited to partner with Frauke as SCIENION continues to build tailored platforms to create the future of health,” stated Holger Eickhoff, CEO of SCIENION.

“I am delighted to welcome Frauke to SCIENION. She is an inspiring leader and experienced company-builder. SCIENION is a global brand trusted by over 1000 diagnostic and life science customers. BICO is confident that Frauke and Holger will be a great team that will leverage SCIENION’s assets and current momentum to lead us into our next chapter of growth,” said Erik Gatenholm, CEO of BICO.

“I’m thrilled to be joining SCIENION and I am honored to partner with Holger, the SCIENION and BICO team to do just that: carrying on the company’s mission of bringing a universe of precision liquid handling solutions to diagnostic, pharma and life science businesses of any size, anywhere in the world. We have the can-do spirit, capability, trusted brand, talented and diverse global team to engage and serve businesses worldwide, and in doing so create shareholder value for many years to come,” added Frauke Hein.

About BICO

Founded in 2016, BICO (formerly CELLINK) is enabling the future of life-saving treatments by reducing the organ shortage and accelerating drug development by providing accessible life science solutions that combine biology and technology (bioconvergence). The company focuses on developing, manufacturing, selling, and supporting its life sciences equipment, consumables, and reagents for both manufacturing as well as research purposes. BICO has more than 25,000 products in the field, sales in more than 65 countries, delivers to all top 20 pharmaceutical companies, and have been cited in more than 10,000 scientific publications. BICO is listed on Nasdaq Stockholm under: BICO.